AstraZeneca asthma shot hits goal but diabetes drug lags rival - Reuters

Reuters

AstraZeneca asthma shot hits goal but diabetes drug lags rival Reuters But the British drugmaker's established Bydureon medicine for diabetes failed to show a hoped-for benefit in reducing heart risks, putting it at a disadvantage to Novo Nordisk's rival Victoza in the so-called GLP-1 drug class. Novo's next-generation ... and more »